ECSP045409A - Composiciones y metodos para dosificar liposomas de ciertos tamaños a fin de tratar o prevenir enfermedades. - Google Patents

Composiciones y metodos para dosificar liposomas de ciertos tamaños a fin de tratar o prevenir enfermedades.

Info

Publication number
ECSP045409A
ECSP045409A EC2004005409A ECSP045409A ECSP045409A EC SP045409 A ECSP045409 A EC SP045409A EC 2004005409 A EC2004005409 A EC 2004005409A EC SP045409 A ECSP045409 A EC SP045409A EC SP045409 A ECSP045409 A EC SP045409A
Authority
EC
Ecuador
Prior art keywords
liposomes
treat
methods
order
dosage
Prior art date
Application number
EC2004005409A
Other languages
English (en)
Inventor
Wendi V Rodrigueza
Original Assignee
Esperion Luv Dev Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Luv Dev Inc filed Critical Esperion Luv Dev Inc
Publication of ECSP045409A publication Critical patent/ECSP045409A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)

Abstract

(57) Resumen: El presente invento se relaciona con composiciones farmacéuticas compuestas de liposomas y métodos para usar tales liposomas a fin de prevenir, tratar o manejar una variedad de enfermedades y/o condiciones corporales. Los liposomas pueden componerse de vesículas unilamelares largas (LUVs) solas o en combinación con vesículas multilamelares (MLVs), vesículas unilamelares pequeñas (SUVs), u otras terapéuticas. El invento se relaciona con liposomas que tengan ciertos diámetros, administrados a pacientes que usan dosis específicas y/o regímenes de dosificación.
EC2004005409A 2002-04-05 2004-11-04 Composiciones y metodos para dosificar liposomas de ciertos tamaños a fin de tratar o prevenir enfermedades. ECSP045409A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37040902P 2002-04-05 2002-04-05

Publications (1)

Publication Number Publication Date
ECSP045409A true ECSP045409A (es) 2005-03-10

Family

ID=29250522

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005409A ECSP045409A (es) 2002-04-05 2004-11-04 Composiciones y metodos para dosificar liposomas de ciertos tamaños a fin de tratar o prevenir enfermedades.

Country Status (26)

Country Link
US (2) US20040009216A1 (es)
EP (1) EP1501482A1 (es)
JP (1) JP2005527582A (es)
KR (1) KR20050009988A (es)
CN (1) CN1655764A (es)
AP (1) AP2004003157A0 (es)
AU (1) AU2003230800A1 (es)
BR (1) BR0309030A (es)
CA (1) CA2480763A1 (es)
CR (1) CR7563A (es)
EA (1) EA007986B1 (es)
EC (1) ECSP045409A (es)
HR (1) HRP20040915A2 (es)
IL (1) IL164370A0 (es)
IS (1) IS7493A (es)
MA (1) MA27298A1 (es)
MX (1) MXPA04009692A (es)
NO (1) NO20044751L (es)
NZ (1) NZ535900A (es)
OA (1) OA12799A (es)
PL (1) PL372689A1 (es)
RS (1) RS87704A (es)
TN (1) TNSN04190A1 (es)
UA (1) UA80121C2 (es)
WO (1) WO2003086351A1 (es)
ZA (1) ZA200407947B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037271A1 (en) * 2002-10-25 2004-05-06 Vasogen Ireland Limited Cyclooxygenase regulation with ps liposomes
WO2004037270A1 (en) * 2002-10-25 2004-05-06 Vasogen Ireland Limited Cyclooxygenase regulation with pg liposomes
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
EP1658086A2 (en) * 2003-07-21 2006-05-24 Vasogen Ireland Limited Liposomes containing phosphate glycerol groups for treating acute inflammatory condition
US20080260861A1 (en) * 2004-04-07 2008-10-23 The General Hospital Corporation Modulating Lymphatic Function
US20100166838A1 (en) * 2004-11-23 2010-07-01 Wendy Bollinger Bollag Methods And Compositions For Modulating Keratinocyte Function
KR100891595B1 (ko) * 2005-02-28 2009-04-03 주식회사 케이티앤지 혈액 단백질의 삼출을 감소시키는 조성물
KR100768265B1 (ko) * 2005-11-10 2007-10-17 한국화학연구원 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법
JP4395658B2 (ja) * 2005-11-17 2010-01-13 エムジーファーマ株式会社 コレステロール再上昇抑制用組成物およびその用法
US8697120B2 (en) * 2006-05-01 2014-04-15 Johns Hopkins University Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
CN101484588B (zh) 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
BRPI0907008A2 (pt) * 2008-01-31 2015-07-07 Alnylam Pharmaceuticals Inc Métodos otimizados para liberação de dsrna alvejando o gene pcsk9
AU2010223967B2 (en) * 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
SG176553A1 (en) * 2009-05-05 2012-01-30 Muthiah Manoharan Lipid compositions
CN105434354A (zh) * 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 用于治疗深部组织疼痛的制剂
TR201811076T4 (tr) * 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
AU2010260148A1 (en) * 2009-06-15 2012-02-02 Alnylam Pharmaceuticals, Inc. Lipid formulated dsRNA targeting the PCSK9 gene
WO2011059262A2 (ko) * 2009-11-13 2011-05-19 경북대학교 산학협력단 사멸세포 표적 펩타이드, 표지물질 및 치료제를 포함하는 리포솜의 아포토시스 관련 질환의 예방, 치료 또는 치료진단을 위한 용도
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
SG11201503774PA (en) 2012-11-13 2015-06-29 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
KR102096014B1 (ko) 2012-12-05 2020-04-03 알닐람 파마슈티칼스 인코포레이티드 PCSK9 iRNA 조성물 및 그 사용 방법
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CN104422750B (zh) * 2013-09-05 2016-02-10 中国科学院大连化学物理研究所 一种烟叶中磷脂酰乙醇胺与甘油三酯含量的检测方法
US10251897B2 (en) 2014-01-17 2019-04-09 Nishizaki Bioinformation Research Institute GLUT4 endocytosis inhibitor
CN110279654B (zh) * 2019-07-22 2023-02-03 苏州大学附属第一医院 缓释阿司匹林脂质体水凝胶、制备方法及其在制备治疗复发性腰椎间盘突出症药物中的应用
EP4257140A4 (en) * 2020-12-04 2024-11-06 Regimmune Corporation PREPARATION OF LIPOSOMES CONTAINING A CD1D LIGAND COMPOUND WITH IMPROVED PHARMACOKINETICS
US11806507B2 (en) 2020-12-22 2023-11-07 Regina E. HERZLINGER Methods, systems, and apparatus for administering an antibody treatment via infusion
AU2021409558A1 (en) * 2020-12-22 2023-07-20 Regina E. HERZLINGER Methods, systems, and apparatus for administering a monoclonal and/or polyclonal antibody treatment via rapid infusion
US12133966B2 (en) 2020-12-22 2024-11-05 Regina E. HERZLINGER Methods, systems, and apparatus for administering an antibody treatment via infusion
WO2025159416A1 (ko) * 2024-01-22 2025-07-31 연세대학교 산학협력단 단핵구에 탑재되는 리포좀을 포함하는 약물 전달체

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
JPS5348976A (en) * 1976-10-18 1978-05-02 Nippon Zeon Co Ltd Mass transfer apparatus of hollow fiber type
US4186183A (en) * 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4247393A (en) * 1979-01-11 1981-01-27 Wallace Richard A Hemodialysis assist device
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
DE3276390D1 (en) * 1981-09-10 1987-06-25 Intermedicat Gmbh Method for the selective extracorporeal precipitation of low-density lipoproteins from serum or plasma
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4532089A (en) * 1984-01-14 1985-07-30 Northwestern University Method of preparing giant size liposomes
US4663167A (en) * 1984-04-16 1987-05-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US4978654A (en) * 1984-04-16 1990-12-18 Board Of Regents, The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
EP0223831B1 (en) * 1985-05-22 1992-07-15 Liposome Technology, Inc. Liposome inhalation method and system
US4774085A (en) * 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4812314A (en) * 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US5258499A (en) * 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5219994A (en) * 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
US5015483A (en) * 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
WO1990012595A1 (en) * 1989-04-18 1990-11-01 Vestar, Inc. Liposomal targeting of ischemic tissue
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE4018767A1 (de) * 1990-06-12 1991-12-19 Braun Melsungen Ag Wirkstofffreie liposomen zur behandlung von atherosklerose
US5231090A (en) * 1990-07-30 1993-07-27 University Of Miami Treatment for hypercholesterolemia
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
JPH04305879A (ja) * 1990-09-12 1992-10-28 Fuji Electric Co Ltd ディスク記憶装置のヘッド操作用可動体の拘束装置
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5405832A (en) * 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
US5219888A (en) * 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
US5250060A (en) * 1992-06-26 1993-10-05 Carbo Paul L Angioplasty apparatus
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US6139871A (en) * 1995-07-26 2000-10-31 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US6312719B1 (en) * 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US5746223A (en) * 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
US5599306A (en) * 1994-04-01 1997-02-04 Localmed, Inc. Method and apparatus for providing external perfusion lumens on balloon catheters
US5622715A (en) * 1994-06-10 1997-04-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of improving renal function
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5674488A (en) * 1994-10-07 1997-10-07 Reich; John J. Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol
DE69527212T2 (de) * 1994-11-23 2003-02-20 Kimberly-Clark Worldwide, Inc. Absorbierender artikel mit einem verbundabsorptionskern
US5489611A (en) * 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5741514A (en) * 1995-08-31 1998-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for reducing serum lipoprotein(a) concentration
US5843474A (en) * 1995-10-11 1998-12-01 Reverse Transport Licensing & Consulting, Inc. Method of dialysis treatment, and dialysis apparatus related thereto
US5846691A (en) * 1996-07-08 1998-12-08 Polyfibron Technologies, Inc. Composite relief image printing plates and methods for preparing same
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
IL145712A0 (en) * 1999-04-01 2002-07-25 Esperion Therapeutics Inc Ether compounds, compositions, and uses thereof
WO2000069412A1 (en) * 1999-05-14 2000-11-23 Esperion Luv Development, Inc. Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
WO2003026588A2 (en) * 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Methods and apparatus for extrusion of vesicles at high pressure

Also Published As

Publication number Publication date
MXPA04009692A (es) 2006-03-08
MA27298A1 (fr) 2005-05-02
AU2003230800A1 (en) 2003-10-27
AP2004003157A0 (en) 2004-12-31
KR20050009988A (ko) 2005-01-26
NZ535900A (en) 2008-08-29
EA200401317A1 (ru) 2005-06-30
OA12799A (en) 2006-07-11
US20040009216A1 (en) 2004-01-15
NO20044751L (no) 2004-12-20
JP2005527582A (ja) 2005-09-15
US20080213351A1 (en) 2008-09-04
IS7493A (is) 2004-10-08
CN1655764A (zh) 2005-08-17
EA007986B1 (ru) 2007-02-27
HRP20040915A2 (en) 2005-02-28
WO2003086351A1 (en) 2003-10-23
CA2480763A1 (en) 2003-10-23
TNSN04190A1 (en) 2007-03-12
PL372689A1 (en) 2005-07-25
ZA200407947B (en) 2006-07-26
EP1501482A1 (en) 2005-02-02
UA80121C2 (en) 2007-08-27
BR0309030A (pt) 2005-02-01
CR7563A (es) 2005-09-20
IL164370A0 (en) 2005-12-18
RS87704A (sr) 2006-12-15

Similar Documents

Publication Publication Date Title
TNSN04190A1 (en) Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
AR045630A1 (es) Formas de dosificacion de azitromicina con efectos secundarios reducidos
PL1708686T3 (pl) Doustna forma dawkowania fentanylu w postaci musującej o charakterze liniowym oraz sposoby jego podawania
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
CO5261556A1 (es) Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
CR8352A (es) Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
RU2010147287A (ru) Комбинированная композиция
EA201590166A1 (ru) Комбинированная терапия для лечения рассеянного склероза
ES2721899T3 (es) Composiciones farmacéuticas que comprenden fentanilo para su administración intranasal
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
AR052047A1 (es) Metodos de uso y composiciones comprendiendo moduladores de pde4 para el tratamiento prevencion y control de inflamacion de las vias respiratorias
IL162768A0 (en) Method of treatment of a patient requiring analgesia
BRPI0415651A (pt) métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica
ES2179729B1 (es) Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
ATE251894T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung
BRPI0307816F1 (pt) Usos de uma composição de carga farmacêutica oral líquida para forma de dosagem de cápsula macia
RU2002129356A (ru) Комбинация лекарственных средств для лечения головной боли, содержащая нестероидное противовоспалительное лекарственное средство
TW200611697A (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
MD3381G2 (ro) Metodă de tratament al parotiditei cronice la copii
AR043129A1 (es) Combinacion de farmacos antidiabeticos
HK1133829A (en) Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
UY30293A1 (es) Formulaciones de dosificacion oral de polipeptidos resistentes a proteasas y usos de los mismos para tratamiento